TAVR Trumps Surgery in Trial for High-Risk Heart Patients

TAVR has changed the landscape for high-risk patients in need of new aortic heart valves. Now, research shows it also has lasting effects.

1:30 PM

Author | Shantell M. Kirkendoll

For high-risk patients who need new aortic heart valves — and the doctors who treat them — options used to be in short supply.

The minimally invasive procedure known as TAVR has changed the landscape. Now, new research shows it has lasting effects for high-risk patients.

G. Michael Deeb, M.D., professor of cardiac surgery at the University of Michigan Frankel Cardiovascular Center, presented positive results about TAVR, or transcatheter aortic valve replacement, during a featured clinical research session at the American College of Cardiology Scientific Sessions in Chicago.

In the High Risk Study of CoreValve U.S. Pivotal Trial, Deeb and colleagues compared TAVR using the Medtronic CoreValve System with surgical aortic valve replacement out to three years. TAVR showed superior outcomes. The findings were simultaneously published in the Journal of the American College of Cardiology.

The new data support the viability of TAVR out to three years with no signal of a significant increase in mean gradient or aortic regurgitation.
G. Michael Deeb, M.D.

Of the 407 patients studied, 46.7 percent who had TAVR were alive and stroke-free three years later compared with 37.3 percent of patients who had surgery.

Patients treated with the CoreValve System showed superior outcomes compared to surgery for all strokes (12.6 percent vs. 19.0 percent). All-cause mortality continued to be numerically lower for TAVR compared with surgery-treated patients (32.9 percent vs. 39.1 percent).

"It's reassuring to see that the CoreValve High Risk Study continues to show that TAVR is superior to surgery at three years for the combined endpoint of mortality and stroke, which has the most important impact on patients," says Deeb, the Herbert Sloan Collegiate Professor of Cardiac Surgery. "Most importantly, the new data support the viability of TAVR out to three years with no signal of a significant increase in mean gradient or aortic regurgitation."

TAVR allows doctors to reach the aortic valve using hollow tubes called catheters rather than opening a patient's chest during surgery. The procedure is a boon to patients for whom open-heart surgery is too risky.

The U.S Food and Drug Administration approved the CoreValve System in 2014. It was the first TAVR device approved in the United States for valve-in-valve procedures in both high-risk and extreme-risk patients with failed surgical valves.

The surgeons and interventional cardiologists at the U-M Frankel Cardiovascular Center have performed more than 640 TAVR procedures, making the program one of the busiest in the country. U-M researchers participated in clinical trials leading to the TAVR devices on the market today.

"One of the great aha moments in my life was seeing the difference between a post-procedure transcatheter aortic valve patient versus a surgical valve patient," says Deeb. "After the (TAVR) procedure they're ready to go. They want to go home. They want to get back into life. It's that dramatic."


More Articles About: Lab Report Transcatheter Aortic Valve Replacement (TAVR) Cardiovascular: Treatment & Surgery
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories tavr stroke blue cardiovascular red inside blue background
Health Lab
Hospitals without highest stroke care designation may miss them after heart procedure
Using stroke as a measure of quality after TAVR could put stroke centers at a disadvantage, the study suggests
Microscopic image of bone marrow with pink and white hues
Health Lab
Novel risk score for cardiovascular complications after bone marrow transplant
More bone marrow transplants, also known as hematopoietic stem cell transplantation, are being offered to older patients, a population at greater risk of cardiovascular disease.
Provider takes a pulse oximetry reading from a patient's finger
Health Lab
Inaccurate pulse oximeter readings could limit transplants, heart pumps for Black patients with heart failure
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heart failure to receive potentially lifesaving treatments, such as heart pumps and transplants
News Release
Statewide cardiovascular consortium, hosted at Michigan Medicine, receives national award for patient safety, quality efforts
A collaborative partnership dedicated to improving statewide cardiovascular care and outcomes — hosted at Michigan Medicine — received national recognition for efforts in patient safety and quality. BMC2 received the award for its significant improvements in the documentation of radiation use, a decrease in high-dose radiation exposure and reduction in opioid prescribing rates for patients.
Health Lab
Teen turns EKG heart readings into art
Teenage heart patient transforms EKG paper into art creations, sold as notecards to support research at University of Michigan Health C.S. Mott Children’s Hospital
doctor heart floating stethoscope
Health Lab
AI model predicts death, complications for patients undergoing angioplasty, stents
Researchers at Michigan Medicine developed an AI-driven algorithm that accurately predicts death and complications after PCI — which could emerge as a tool for clinicians as they determine treatment for blocked heart arteries.